Cargando…
Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events
ICRF-193, a novel noncleavable, complex-stabilizing type topoisomerase (topo) II inhibitor, has been shown to target topo II in mammalian cells (Ishida, R., T. Miki, T. Narita, R. Yui, S. Sato, K. R. Utsumi, K. Tanabe, and T. Andoh. 1991. Cancer Res. 51:4909-4916). With the aim of elucidating the ro...
Formato: | Texto |
---|---|
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2290951/ https://www.ncbi.nlm.nih.gov/pubmed/8089169 |
Ejemplares similares
-
A comprehensive structural analysis of the ATPase domain of human DNA topoisomerase II beta bound to AMPPNP, ADP, and the bisdioxopiperazine, ICRF193
por: Ling, Elise M., et al.
Publicado: (2022) -
Casein kinase II–dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast
por: Nakazawa, Norihiko, et al.
Publicado: (2019) -
DNA binding activity of the proximal C-terminal domain of rat DNA topoisomerase IIβ is involved in ICRF-193-induced closed-clamp formation
por: Kawano, Shinji, et al.
Publicado: (2020) -
Different Susceptibilities of Postmitotic Checkpoint‐proficient and ‐deficient Balb/3T3 Cells to ICRF‐193, a Catalytic Inhibitor of DNA Topoisomerase II
por: Nishida, Keiko, et al.
Publicado: (2001) -
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity
por: Bavlovič Piskáčková, Hana, et al.
Publicado: (2021)